|
May 11
|
Earnings Release: Here's Why Analysts Cut Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target To US$8.00
|
|
May 8
|
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 8
|
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
|
|
May 2
|
Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know
|
|
May 2
|
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
|
|
May 1
|
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
|
|
Apr 16
|
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
|
|
Apr 15
|
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
|
|
Apr 15
|
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
|
|
Mar 27
|
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
|
|
Mar 20
|
Do Options Traders Know Something About Marinus (MRNS) Stock We Don't?
|
|
Mar 7
|
Marinus Pharmaceuticals Inc (MRNS) Reports Full Year and Q4 2023 Financial Results
|
|
Mar 7
|
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript
|
|
Mar 6
|
Q4 2023 Marinus Pharmaceuticals Inc Earnings Call
|
|
Mar 5
|
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 5
|
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Feb 6
|
Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?
|
|
Jan 2
|
Those who invested in Marinus Pharmaceuticals (NASDAQ:MRNS) a year ago are up 156%
|
|
Dec 7
|
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
|
|
Jul 3
|
Strength Seen in Marinus Pharmaceuticals (MRNS): Can Its 5.4% Jump Turn into More Strength?
|